Sutent

New Products: BPH surgical robot granted FDA de novo requestOther products highlighted in this round-up include a plate for studying infections caused by the long-term use of catheters and a new indication for sunitinib malate (SUTENT).
Sunitinib vs. everolimus: PFS, toxicity differ in studyIn a head-to-head comparison, sunitinib (Sutent) prolonged radiographic progression-free survival compared with everolimus (Afinitor), but with greater toxicity, in patients with specific subtypes of metastatic renal cell carcinoma and non-clear cell histology, said Andrew J. Armstrong, MD, MSc.
Adjuvant therapy fails in locally advanced kidney CaTwo angiogenesis inhibitors that are widely used in metastatic renal cell carcinoma did not improve survival compared with placebo when used as adjuvant treatment, a new study found.
Best of GU Cancers 2015: Dr. Thrasher’s picks and moreNew, large-scale studies on active surveillance, IMRT complications, and robotic versus open prostatectomy were among the highlights of this year’s Genitourinary Cancers Symposium.
Best of AUA 2014: Kidney CancerMonish Aron, MD, presents the take home messages on kidney cancer from the AUA annual meeting in Orlando, FL.
RCC sequencing: One good answerThe take-home message is that for sorafenib and sunitinib, sequencing does not appear to be drug dependent and either can be used as first- or second-line therapy.
Sequential therapies for metastatic renal cell carcinoma yield similar resultsThe sequential use of two targeted treatments for metastatic renal cell carcinoma appears to yield similar total progression-free survival regardless of the order in which they are given, phase III study results indicate.
Study may signify shift in RCC standard of careThe tyrosine kinase inhibitors pazopanib (Votrient) and sunitinib (Sutent) had similar benefits in delaying progression of advanced renal cell carcinoma, but the safety profile and many measures of quality of life favored pazopanib, according to data from a recently published multicenter study.
Metastatic renal cell carcinoma agent nearly doubles survivalA personalized immunotherapy (AGS-003) nearly doubled expected progression-free survival and overall survival when added to standard sunitinib (Sutent) in patients with unfavorable-risk metastatic renal cell carcinoma, according to results from a single-arm phase II study.